Bullboard - Stock Discussion Forum Arch Biopartners Inc V.ARCH

Alternate Symbol(s): ACHFF

Technology Scientific & Technical Instruments

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is... see more

Add To Watchlist

TSXV:ARCH - Post Discussion

Arch Biopartners Inc > Why do Phase II trials fail?

View:

Post by PeptidePete on Sep 17, 2024 8:34pm

Why do Phase II trials fail?

Failures in phase II testing overall usually occur because: 1) previously unknown toxic side effects occur (50%); 2) the trials show insufficient efficacy to treat the medical condition being tested (30%); or 3) commercial viability looks poor (15%).

Phase II trials in drug devopment and adaptive trial design

144